Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Hematopoietic Syndrome Due to Acute Radiation Syndrome

In brief

The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.

Key facts

Study ID
NCT02343133
Run by
Neumedicines Inc.
People needed
200
Starts
2015-01-01
Expected to finish
2016-04-01
Last updated by the study team
2018-11-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.